{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:27:55Z","timestamp":1789126075215,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    Due to the high morbidity and mortality of the coronavirus disease 2019 (COVID-19) in patients with malignancy, the necessity of vaccination in this group of patients became particularly important. Although a large number of studies have reported the safety of COVID-19 vaccination in multiple myeloma (MM) patients, the effect of the COVID-19 vaccine on MM relapse has not yet been reported. Here, we report a case of a possible association between relapse of MM and COVID-19 vaccination with Sinopharm\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , an inactivated virus vaccine, in a patient with MM who has remained in complete remission for about 4 years. The MM relapse in the patient was diagnosed by both clinical findings and laboratory workup including serum protein electrophoresis, bone marrow aspiration, and biopsy. Despite this possible association between COVID-19 vaccination and MM relapse in the patient, given its importance in reducing mortality and having an acceptable safety profile, the COVID-19 vaccine should be administered to all cancer patients. However, careful monitoring and follow-up are recommended in patients with MM after COVID-19 vaccination.\n                  <\/jats:p>","DOI":"10.4103\/jrpp.jrpp_21_24","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T03:00:39Z","timestamp":1727406039000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Is there a Possible Association between Multiple Myeloma Relapse and Coronavirus Disease 2019 Vaccination? A Case Report"],"prefix":"10.4103","volume":"13","author":[{"given":"Nasrin","family":"Shirzad-Yazdi","sequence":"first","affiliation":[{"name":"Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran"},{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Namdari","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahid","family":"Noorani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"R1-20241010","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1038\/s41467-021-23938-8","article-title":"Controlling the pandemic during the SARS-CoV-2 vaccination rollout","volume":"12","author":"Viana","year":"2021","journal-title":"Nat Commun"},{"key":"R3-20241010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/vaccines10060920","article-title":"Vaccination with the inactivated vaccine (Sinopharm BBIBP-CorV) ensures protection against SARS-CoV-2 related disease","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R4-20241010","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41409-018-0112-x","article-title":"Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation","volume":"53","author":"Pandit","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R5-20241010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma:A consensus of the European myeloma network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"R6-20241010","doi-asserted-by":"crossref","first-page":"e936896","DOI":"10.12659\/AJCR.936896","article-title":"A clinical case of COVID-19 vaccine-associated Guillain-Barr\u00e9syndrome","volume":"23","author":"Hilts","year":"2022","journal-title":"Am J Case Rep"},{"key":"R7-20241010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20503121211027462","article-title":"COVID-19 and aging:Identifying measures of severity","volume":"9","author":"Neves","year":"2021","journal-title":"SAGE Open Med"},{"key":"R8-20241010","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jinf.2020.03.005","article-title":"Clinical features of COVID-19 in elderly patients:A comparison with young and middle-aged patients","volume":"80","author":"Liu","year":"2020","journal-title":"J Infect"},{"key":"R9-20241010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaoncol.2021.5942","article-title":"Neutralizing antibody testing in patients with multiple myeloma following COVID-19 vaccination","volume":"8","author":"Terpos","year":"2022","journal-title":"JAMA Oncol"},{"key":"R10-20241010","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"R11-20241010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07357907.2021.1992420","article-title":"Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy","volume":"40","author":"Ariamanesh","year":"2022","journal-title":"Cancer Invest"},{"key":"R12-20241010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","article-title":"Side effects and perceptions following sinopharm COVID-19 vaccination","volume":"111","author":"Saeed","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R13-20241010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment:Preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R14-20241010","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3201\/eid2711.211723","article-title":"Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma","volume":"27","author":"Choi","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"R15-20241010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/ckj\/sfac134","article-title":"Idiopathic nephrotic syndrome relapse following COVID-19 vaccination:A series of 25 cases","volume":"15","author":"Hummel","year":"2022","journal-title":"Clin Kidney J"},{"key":"R16-20241010","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s11255-022-03258-6","article-title":"Relapse of minimal change disease and inactivated SARS-CoV-2 vaccination","volume":"54","author":"Sriwijitalai","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"R17-20241010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10067-021-05963-6","article-title":"Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus","volume":"41","author":"Barbhaiya","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R18-20241010","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(21)00108-9","article-title":"Flare of rheumatoid arthritis after COVID-19 vaccination","volume":"3","author":"Terracina","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R19-20241010","doi-asserted-by":"crossref","first-page":"897275","DOI":"10.3389\/fneur.2022.897275","article-title":"Case report:Exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis:A case series","volume":"13","author":"Quintanilla-Bord\u00e1s","year":"2022","journal-title":"Front Neurol"},{"key":"R20-20241010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"R21-20241010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/25785826.2021.1999786","article-title":"New mimic of relapse or regional lymph node metastasis in a cancer survivor:A case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake","volume":"45","author":"Tsumura","year":"2022","journal-title":"Immunol Med"},{"key":"R22-20241010","first-page":"592891","article-title":"COVID-19-induced modifications in the tumor microenvironment:Do they affect cancer reawakening and metastatic relapse?Front Oncol","volume":"10","author":"Francescangeli","year":"2020"},{"key":"R24-20241010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/bmt.2012.151","article-title":"Patterns of relapse and progression in multiple myeloma patients after auto-SCT:Implications for patients'monitoring after transplantation","volume":"48","author":"Zamarin","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R25-20241010","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/bloodadvances.2020003996","article-title":"Early detection of treatment failure and early rescue intervention in multiple myeloma:Time for new approaches","volume":"5","author":"Lahuerta","year":"2021","journal-title":"Blood Adv"},{"key":"R26-20241010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-023-00877-9","article-title":"Global disparities in patients with multiple myeloma:A rapid evidence assessment","volume":"13","author":"Mateos","year":"2023","journal-title":"Blood Cancer J"},{"key":"R27-20241010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_21_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:07:02Z","timestamp":1787774822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_21_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_21_24","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}